MGF

MGF (Mechano Growth Factor) is a splice variant of IGF‑1 that activates satellite cells to support muscle repair and growth, and it is used off‑label primarily for muscle growth and recovery, with some reports also citing injury healing and tissue repair. Community users most often report a dose around 15 mg per day (with a reported range of 200 µg to 30 mg) and usually do not specify timing or cycling, whereas clinician guidance typically recommends 200 µg administered once weekly by intramuscular injection. Because MGF carries no FDA‑approved indication, all human use remains off‑label or compounded, which is the primary consideration when weighing its use.

Half-life~7 min

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyno dataClinicalResearchSideEffectsno dataAnecdotalEfficacyAnecdotalSideEffectsPrice0.42.13.12.0

Measured on 4 of 6 axes

Research Evidence

Evidence shape

Overall, the evidence tier for MGF is classified as animal‑only, which means that the only information currently available at this time comes exclusively from preclinical mechanistic research. In summary, the peptide maps to a single indication, possesses zero registered human trials, and has no completed studies reported. Consequently, there is an absence of human data, posted results, or any trial completion to date, which together signal a total lack of clinical evidence for MGF.

Depthhow much
0 registered trials
Breadthhow many areas
1 indication mapped
1 animal-only
Qualityhow rigorous
No completed trials
Breadth and depth17 rows captured
Human
direct clinical signal
0
Animal
translational support
12
In vitro
mechanistic support
5
HighMediumLow

Anecdotal efficacy

1
Hong Kong
20 mg×10
$40.00
$2/mg
2
CN
20 mg×10
$79.00
$3.95/mg
3
--
5 mg
$22.85
$4.57/mg
4
US
5 mg
$32.99
$6.6/mg
5
GB
2 mg
$13.42
$6.71/mg
6
GB
2 mg
$13.42
$6.71/mg

price offers can be sorted by column · 6 out-of-stock offers not shown

1-6 of 45

MGF dosing & protocol

How MGF is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols
Typical dose
—
0
10 mg
20 mg
30 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

Clinician practice
Doctor & published-protocol guidance · n = 1
Typical dose
200 µg
typical
0
10 mg
20 mg
30 mg
across 1 dosed source · darker = more agree
By reported cadence
Weekly200 µg · n=1
Frequency
weekly
Route
IM

One clinician source documents 200 mcg administered intramuscularly once weekly.

1 source
Anecdotal
Community-reported real-world use · n = 12
Typical dose
15 mg200 µg – 30 mg
typical
0
10 mg
20 mg
30 mg
distribution of 12 reported doses · darker = more
Frequency
unspecified
Route
subQ

Reported subcutaneous doses across 12 community sources span a wide range — from 200 mcg to 30 mg — with no dominant figure; the only cadence reported is 500 mcg five times per week from a single source. Frequency is unspecified for the rest, and no cycling patterns were noted.

12 sources